CDKN2A and glioma: Low grade glioma and high grade GBM tumors with homologous deletion of CDKN2A had significantly higher levels of STK17A, suggesting that those tumors with deactivation of p53 due to CDKN2A loss may compensate by upregulating STK17A (Figure S9).